BioPharmSignal logoBioPharmSignal

Biotech News

Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat

Certara (CERT)CertaraCompany update

Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence Updated 2026 guidance to be provided upon transaction close RADNOR, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today

Related news

CERTCertara2026-07-07 12:00 EST

Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit

CERTCertara2026-03-03 13:00 EST

Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib

View all latest news

Certara

Model-Informed Drug Development Certara provides biosimulation software and technology-enabled services used throughout drug discovery, clinical development and regulatory review. Its tools help predict how medicines behave in different patients and dosing scenarios. Software Portfolio The company's software includes pharmacokinetic,...

Recent company news

CERTCertara2026-08-04 11:00 EST

Certara Reports Second Quarter 2026 Financial Results

CERTCertara2026-07-15 20:15 EST

Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026

CERTCertara2026-07-07 12:00 EST

Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit

CERTCertara2026-06-17 20:30 EST

Certara Announces CFO Transition

CERTCertara2026-05-18 20:15 EST

Certara to Participate in Upcoming Investor Conferences

Stock data

Close
8.13 USD
Market cap
874.27M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States